04/16/2026
Peptides!
Update as of 4.15.26 from the FDA. We will know more in July. This will allow these previously labeled category 2 research peptides to category 1 and allowable for compounding by FDA regulated facilities.
Big shift happening in the peptide space—and it matters for both patient safety and clinical integrity.
For a while now, many peptides were pushed into a high-risk category, limiting access through legitimate medical channels. The unintended result? A growing gray/black market with zero quality control, unknown sourcing, and increased risk to patients.
While there are reputable companies providing these products to providers, they are still considered research peptides.
Now, things are starting to move in a better direction.
Several peptides are being re-evaluated through a formal, science-based review process, where independent experts will assess safety, clinical data, and appropriate use. This is exactly how medicine should work—through evidence, oversight, and accountability.
Peptides currently under review include:
• BPC-157
• Thymosin Beta-4 fragment
• Epitalon
• GHK-Cu (injectable)
• MOTS-c
• DSIP
• Dihexa Acetate
• Ibutamoren
• Melanotan II
• KPV
• Semax
• LL-37
What this means for you: This is a step toward safer, regulated access—moving away from unreliable sources and back into a medical framework where quality, dosing, and outcomes are properly managed.
At NPS Wellness & Aesthetics, we will always:
• Follow the science
• Prioritize patient safety
• Stay ahead of regulatory changes
• Offer treatments that are both effective and responsible
If you’ve been curious about peptides or unsure what’s safe, this is exactly why working with a medical provider who understands both the science and the regulations matters.
Questions about peptides or how they fit into your plan of care? We’re here to guide you.
